Leveraging Interleukin-1 Blockade as a Therapeutic Strategy for Cardiac Sarcoidosis: Rationale and Design for the RandomizEd PhAse II TrIal of Rilonacept in Subjects With Cardiac Sarcoidosis (REPAIR-CS)

Andrew N. Rosenbaum; ANJALI WAGLE; Courtney L. Meuth; Sheldon Wang; J F Paolini; MELANIE A. BRATCHER; Panithaya Chareonthaitawee; Nisha A. Gilotra

doi:10.1016/j.cardfail.2026.03.010

Leveraging Interleukin-1 Blockade as a Therapeutic Strategy for Cardiac Sarcoidosis: Rationale and Design for the RandomizEd PhAse II TrIal of Rilonacept in Subjects With Cardiac Sarcoidosis (REPAIR-CS)

Journal of Cardiac Failure 2026

View at publisher

Authors: Andrew N. Rosenbaum, ANJALI WAGLE, Courtney L. Meuth, Sheldon Wang, J F Paolini, MELANIE A. BRATCHER, Panithaya Chareonthaitawee, Nisha A. Gilotra

DOI: 10.1016/j.cardfail.2026.03.010

Cited by: 1

References: 70

Fields of Study & Subjects

Sarcoidosis and Beryllium Toxicity Research Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis Pericarditis and Cardiac Tamponade

Publication details

Journal / source: Journal of Cardiac Failure
Publisher: Elsevier BV
Volume: 32
Issue: 5
Pages: 877–887
Publication date: 1 May 2026
Language: EN

References 70